Transcode Therapeutics annual net debt
2020
2022
2023
2024
2025
Transcode Therapeutics Net Debt Growth & History (RNAZ)
Transcode Therapeutics's net debt was −$17.8M for fiscal 2025.
View full Transcode Therapeutics company overviewTranscode Therapeutics annual net debt history
| Fiscal year | Period ended | Net debt | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$17.8M | −$12.0M | — |
| 2024 | 2024-12-31 | −$5.8M | −$3.5M | — |
| 2023 | 2023-12-31 | −$2.3M | $2.7M | — |
| 2022 | 2022-12-31 | −$5.0M | — | — |
| 2020 | 2020-12-31 | $1.3M | — | — |
Transcode Therapeutics quarterly net debt
Q4.20
Q2.21
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q2.26
| Fiscal quarter | Period ended | Net debt | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$7.7M | −$356,167 | — |
| Q4 2025 | 2025-12-31 | −$17.8M | −$12.0M | — |
| Q3 2025 | 2025-09-30 | −$2.8M | −$1.1M | — |
| Q2 2025 | 2025-06-30 | −$7.4M | −$4.2M | — |
| Q1 2025 | 2025-03-31 | −$11.6M | −$7.0M | — |
| Q4 2024 | 2024-12-31 | −$5.8M | −$3.5M | — |
| Q3 2024 | 2024-09-30 | −$1.7M | $5.1M | — |
| Q2 2024 | 2024-06-30 | −$3.1M | −$218,123 | — |
| Q1 2024 | 2024-03-31 | −$4.6M | −$3.7M | — |
| Q4 2023 | 2023-12-31 | −$2.3M | — | — |
| Q3 2023 | 2023-09-30 | −$6.9M | — | — |
| Q2 2023 | 2023-06-30 | −$2.9M | — | — |
| Q1 2023 | 2023-03-31 | −$854,425 | — | — |
| Q2 2021 | 2021-06-30 | $2.0M | — | — |
| Q4 2020 | 2020-12-31 | $1.3M | — | — |
Transcode Therapeutics net debt trends
Over the last five fiscal years, Transcode Therapeutics's net debt decreased from $1.3M to −$17.8M, a change of −$19.1M. The latest reported quarter, Q2 2026, shows −$7.7M.
About the metric
What net debt means
Net debt compares a company’s interest-bearing debt with its cash and cash equivalents. Positive net debt means debt exceeds cash, while a negative value indicates the company has more cash than debt on this measure.
Calculation and source
How net debt is calculated
TickerStat calculates net debt as total interest-bearing debt minus cash and cash equivalents at the same reporting-period end. Short-term investments are not subtracted because they are not included in the standardized cash series. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Transcode Therapeutics source filings ↗